

**Form 605**Corporations Act 2001  
Section 671B**Notice of ceasing to be a substantial holder**

To Company Name/Scheme THE HYDRATION PHARMACEUTICALS COMPANY LIMITED (ASX: HPC)

ACN/ARSN 620 385 677

**1. Details of substantial holder(1)**

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED ("HPC")

Name

ACN/ARSN (if applicable) 620 385 677

The holder ceased to be a  
substantial holder on14 / 12 / 2023

The previous notice was given to the company on

14 / 06 / 2023

The previous notice was dated

14 / 06 / 2023**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
	SEE ANNEXURE A				

**3. Changes in association**

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

**4. Addresses**

The addresses of persons named in this form are as follows:

Name	Address
HPC	c/- cdPlus Corporate Services Pty Ltd, Rialto South Tower, Level 42, 525 Collins Street, Melbourne VIC 3000

**Signature**

print name

Victoria Nadalin

capacity

Company Secretary

sign here

*Victoria Nadalin*

date 14 / 12 / 2023

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
- (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
- See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

## Annexure A

This is annexure A of 1 page referred to in Form 605 Notice of ceasing to be a substantial holder

Company Name and ACN: The Hydration Pharmaceuticals Company Limited ACN 620 385 677

Date: 14 December 2023

Signature: *Victoria Wadala*

### 2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: nature

Date of Change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
13/12/2023	The Hydration Pharmaceuticals Company Limited	Ceasing to have a technical relevant interest in 6,671,720 shares upon release of those shares from voluntary escrow	Nil	6,671,720 fully paid ordinary shares	6,671,720
13/12/2023	The Hydration Pharmaceuticals Company Limited	Ceasing to have a technical relevant interest in 2,334,620 shares upon release of those shares from mandatory escrow	Nil	2,334,620 fully paid ordinary shares	2,334,620
14/12/2023	The Hydration Pharmaceuticals Company Limited	Ceasing to have a technical relevant interest in 885,625 shares upon release of those shares from voluntary escrow	Nil	885,625 fully paid ordinary shares	885,625
14/12/2023	The Hydration Pharmaceuticals Company Limited	Ceasing to have a technical relevant interest in 15,166,671 shares upon release of those shares from mandatory escrow	Nil	15,166,671 fully paid ordinary shares	15,166,671